It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2025/2026
The following technology appraisals have been endorsed during 2025/26. Information on technology appraisals endorsed in previous years can be found on the homepage.
March 2026
TA1138 - Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer
TA1136 - Bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer
- This guidance updates and replaces NICE Technology Appraisal TA212 and partially updates and replaces NICE Technology Appraisals TA118 & TA242, which have all been previously endorsed by DoH.’
TA1134 - Dupilumab for treating severe chronic rhinosinusitis with nasal polyps
TA1133 - Belantamab mafodotin with pomalidomide and dexamethasone for previously treated multiple myeloma
TA1130 - Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
TA1131 - Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
TA1129 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
- This guidance updates and replaces NICE Technology Appraisal TA673, endorsed by the DoH in March 2021
February 2026
TA1128 - Targeted-release budesonide for treating primary IgA nephropathy
- This guidance updates and replaces NICE Technology Appraisal TA937, endorsed by the DoH in January 2024.
TA1127 - Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer
TA1126 - Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
TA1122 - Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
TA1121 - Acoramidis for treating transthyretin amyloidosis with cardiomyopathy
TA1120 - Avelumab with axitinib for untreated advanced renal cell carcinoma
- This guidance updates and replaces NICE Technology Appraisal TA645, endorsed by the DoH in September 2020’.
TA1119 - Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
- This guidance updates and replaces NICE Technology Appraisal TA663, endorsed by the DoH in January 2021’.
January 2026
TA1117 - Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
TA1116 - Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
TA1115 - Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy
December 2025
TA1114 - Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
TA1113 - Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma
TA1110 - Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer
- This guidance updates and replaces NICE Technology Appraisal TA721, endorsed by the DoH in September 2021.
November 2025
TA1109 - Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer
TA1108 - Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
TA1107 - Delgocitinib for treating moderate to severe chronic hand eczema
TA1106 - Cabotegravir for preventing HIV-1 in adults and young people
TA1103 - Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor
TA1101 - Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over
October 2025
TA1099 - Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy
TA1098 - Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable
TA1097 - Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable
September 2025
TA1096 - Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis
TA1095 - Guselkumab for previously treated moderately to severely active Crohn's disease
TA1094 - Guselkumab for treating moderately to severely active ulcerative colitis
TA1093 - Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over
TA1092 - Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
TA1091 - Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments
TA1090 - Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma
TA1088 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
- Note this guidance has been updated and replaced by NICE Technology Appraisal TA1140 - Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over, endorsed by the DoH in April 2026
TA1087- Betula verrucosa for treating moderate to severe allergic rhinitis or conjunctivitis caused by tree pollen
August 2025
TA1086 - Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrence
TA1085 - Vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over
TA1081 - Zanubrutinib for treating relapsed or refractory mantle cell lymphoma
TA1080 - Mirikizumab for preciously treated moderately to severely active Crohn's disease
TA1079 - Fruquintinib for previously treated metastatic colectoral cancer
July 2025
TA1077 - Nemolizub for treating moderate to severe atopic dermatitis in people in 12 years and over
TA1075 - Dapagliflozin for treating chronic kidney disease
- Note this guidance updates and replaces NICE Technology Appraisal TA775, endorsed by the DoH in March 2022
TA1074 - Sparsentan for treating primary IgA nephropathy
TA1073 - Marstacimab for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodiesCE
TA1071 - Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
- Note this guidance updates and replaces NICE Technology Appraisal TA823, endorsed by the DoH in October 2022
June 2025
TA1070 - Spesolimab for treating generalised pustular psoriasis flares
TA1069 - Efgartigimod for treating antibody-positive generalised myasthenia gravis
TA1067 - Linzagolix for treating symptoms of endometriosis
TA1066 - Somapacitan for treating growth hormone deficiency in people 3 to 17 years
TA1065 - Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
TA1064 - Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency | NICE
- Note this guidance updates and replaces NICE Technology Appraisal TA963, endorsed by the DoH in April 2024
TA1063 - Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment | Guidance | NICE
May 2025
TA1062 - Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor
TA 1060 - Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer | Guidance | NICE
TA1059 - Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma | Guidance | NICE
TA1057 - Relugolix–estradiol–norethisterone for treating symptoms of endometriosis | Guidance | NICE
TA1056 - Molnupiravir for treating COVID-19
TA1055 - Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
TA1054 - Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over
TA1053 - Cladribine for treating active relapsing forms of multiple sclerosis
April 2025
TA1051 - Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over
TA1050 - Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over
TA1049 - Overview | Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia | Guidance | NICE
TA1048 - Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable
TA1046 - Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma